Dermata Therapeutics, Inc. SEC filings DRMA
Dermata Therapeutics, Inc. has 371 filings in SEC EDGAR's recent list, going back to Apr 2, 2021. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 20, 2026 | — |
| 25-NSE | Delisting notice | Aug 17, 2026 | — |
| EFFECT | Filing | May 29, 2026 | — |
| CORRESP | Letter to the SEC | May 27, 2026 | — |
| EFFECT | Filing | Jan 29, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2026 | — |
| D | Filing | Jan 7, 2026 | — |
| EFFECT | Filing | Apr 23, 2025 | — |
| CORRESP | Letter to the SEC | Apr 21, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2025 | — |
| EFFECT | Filing | Feb 5, 2025 | — |
| D/A | Filing | Feb 4, 2025 | — |
| CORRESP | Letter to the SEC | Feb 3, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2025 | — |
| D | Filing | Jan 28, 2025 | — |
| D | Filing | Sep 27, 2024 | — |
| EFFECT | Filing | Sep 24, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2024 | — |
| CORRESP | Letter to the SEC | Sep 23, 2024 | — |
| EFFECT | Filing | Jul 12, 2024 | — |
| CORRESP | Letter to the SEC | Jul 10, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2024 | — |
| EFFECT | Filing | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 13, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2023 | — |
| EFFECT | Filing | Jul 27, 2023 | — |
| CORRESP | Letter to the SEC | Jul 25, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2023 | — |
| D | Filing | Jun 12, 2023 | — |
| EFFECT | Filing | Mar 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 14, 2023 | — |
| CORRESP | Letter to the SEC | Mar 14, 2023 | — |
| CORRESP | Letter to the SEC | Mar 13, 2023 | — |
| CORRESP | Letter to the SEC | Mar 13, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2023 | — |
| RW | Filing | Dec 29, 2022 | — |
| EFFECT | Filing | Nov 25, 2022 | — |
| CORRESP | Letter to the SEC | Nov 22, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2022 | — |
| EFFECT | Filing | May 13, 2022 | — |
| CORRESP | Letter to the SEC | May 11, 2022 | — |
| UPLOAD | Letter from the SEC | May 10, 2022 | — |
| DRS | Filing | Jan 11, 2022 | — |
| POS EX | Filing | Aug 13, 2021 | — |
| SEC STAFF LETTER | Filing | Aug 12, 2021 | — |
| EFFECT | Filing | Aug 12, 2021 | — |
| CERT | Filing | Aug 12, 2021 | — |
| 8-A12B | Filing | Aug 11, 2021 | — |
| CORRESP | Letter to the SEC | Aug 10, 2021 | — |
| CORRESP | Letter to the SEC | Aug 10, 2021 | — |
| SEC STAFF LETTER | Filing | Aug 6, 2021 | — |
| CORRESP | Letter to the SEC | Jul 9, 2021 | — |
| SEC STAFF LETTER | Filing | Jul 8, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2021 | — |
| CORRESP | Letter to the SEC | Jul 2, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2021 | — |
| CORRESP | Letter to the SEC | Jun 10, 2021 | — |
| UPLOAD | Letter from the SEC | May 20, 2021 | — |
| DRSLTR | Filing | May 7, 2021 | — |
| DRS/A | Filing | May 7, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2021 | — |
| DRS | Filing | Apr 2, 2021 | — |
Showing 65 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1853816
- Former names
- Dermata Therapeutics, Inc. (until Nov 2, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.